Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry
Background: Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU’s usefulness in everyday clinical practice. Objectives: To assess the effectiveness of S...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Therapeutic Advances in Musculoskeletal Disease |
| Online Access: | https://doi.org/10.1177/1759720X251315138 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576054934372352 |
|---|---|
| author | Giuseppe Lopalco Maria Morrone Fabiola Atzeni Chiara Bazzani Francesco Paolo Bianchi Francesco Paolo Cantatore Roberto Caporali Antonio Carletto Alberto Cauli Maria Sole Chimenti Sergio Colella Fabrizio Conti Addolorata Corrado Ennio Giulio Favalli Alberto Floris Marco Fornaro Rosario Foti Roberta Foti Elena Fracassi Bruno Frediani Stefano Gentileschi Roberto Gorla Elisa Gremese Emanuela Praino Roberta Ramonda Cinzia Rotondo Marco Sebastiani Angelo Semeraro Gianfranco Ferraccioli Giovanni Lapadula Florenzo Iannone |
| author_facet | Giuseppe Lopalco Maria Morrone Fabiola Atzeni Chiara Bazzani Francesco Paolo Bianchi Francesco Paolo Cantatore Roberto Caporali Antonio Carletto Alberto Cauli Maria Sole Chimenti Sergio Colella Fabrizio Conti Addolorata Corrado Ennio Giulio Favalli Alberto Floris Marco Fornaro Rosario Foti Roberta Foti Elena Fracassi Bruno Frediani Stefano Gentileschi Roberto Gorla Elisa Gremese Emanuela Praino Roberta Ramonda Cinzia Rotondo Marco Sebastiani Angelo Semeraro Gianfranco Ferraccioli Giovanni Lapadula Florenzo Iannone |
| author_sort | Giuseppe Lopalco |
| collection | DOAJ |
| description | Background: Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU’s usefulness in everyday clinical practice. Objectives: To assess the effectiveness of SECU by evaluating drug survival and identifying potential predictors of clinical response and treatment discontinuation in patients with moderate-to-severe PsA, using real-world data from the Italian Group for the Study of Early Arthritis (GISEA) registry. Design: This longitudinal retrospective study included PsA patients treated with SECU, spanning from May 2016 to November 2023. Methods: Data from 1045 PsA patients, including 783 with peripheral-only PsA (perPsA) and 262 with peripheral and axial involvement (mixed PsA) were analyzed. Drug survival was estimated by Kaplan–Meier analysis. Clinical outcomes, including Disease Activity Index for Psoriatic Arthritis (DAPSA), Psoriasis Area Severity Index (PASI), Ankylosing Spondylitis Disease Activity Score (ASDAS, C-Reactive Protein (CRP)-based), and Visual Analogue Scale (VAS) measures, were evaluated at baseline and at 6, 12, and 24 months. Adjusted hazard ratios (aHRs) for discontinuing SECU were determined using multivariate Cox regression models. Results: SECU survival at 24 months was 63.24%, significantly higher in mixed PsA compared to perPsA ( p = 0.036). In the overall PsA population, DAPSA scores decreased significantly at 6 months, and further at 24 months (all p < 0.0001). In mixed PsA, ASDAS-CRP scores were significantly reduced at 6 months and remained stable through 24 months (all p < 0.0001). VAS pain scores also improved already at 6 months and continued to improve at 24 months (all p < 0.0001). Higher age (aHR = 0.98, 95% confidence interval (CI): 0.96–0.99, p = 0.007) and lower baseline DAPSA scores (aHR = 1.02, 95% CI: 1.01–1.03, p = 0.014) were associated with greater persistence of SECU treatment. SECU was well tolerated, with no serious adverse events. Conclusion: SECU showed sustained clinical improvements in both peripheral and axial involvement of PsA patients over 24 months, with higher persistence observed in mixed PsA patients. Our findings highlight the favorable clinical and safety profile of SECU in real world. |
| format | Article |
| id | doaj-art-76a97d9395014456a521d95620915053 |
| institution | Kabale University |
| issn | 1759-7218 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Musculoskeletal Disease |
| spelling | doaj-art-76a97d9395014456a521d956209150532025-01-31T12:03:44ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182025-01-011710.1177/1759720X251315138Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA RegistryGiuseppe LopalcoMaria MorroneFabiola AtzeniChiara BazzaniFrancesco Paolo BianchiFrancesco Paolo CantatoreRoberto CaporaliAntonio CarlettoAlberto CauliMaria Sole ChimentiSergio ColellaFabrizio ContiAddolorata CorradoEnnio Giulio FavalliAlberto FlorisMarco FornaroRosario FotiRoberta FotiElena FracassiBruno FredianiStefano GentileschiRoberto GorlaElisa GremeseEmanuela PrainoRoberta RamondaCinzia RotondoMarco SebastianiAngelo SemeraroGianfranco FerraccioliGiovanni LapadulaFlorenzo IannoneBackground: Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU’s usefulness in everyday clinical practice. Objectives: To assess the effectiveness of SECU by evaluating drug survival and identifying potential predictors of clinical response and treatment discontinuation in patients with moderate-to-severe PsA, using real-world data from the Italian Group for the Study of Early Arthritis (GISEA) registry. Design: This longitudinal retrospective study included PsA patients treated with SECU, spanning from May 2016 to November 2023. Methods: Data from 1045 PsA patients, including 783 with peripheral-only PsA (perPsA) and 262 with peripheral and axial involvement (mixed PsA) were analyzed. Drug survival was estimated by Kaplan–Meier analysis. Clinical outcomes, including Disease Activity Index for Psoriatic Arthritis (DAPSA), Psoriasis Area Severity Index (PASI), Ankylosing Spondylitis Disease Activity Score (ASDAS, C-Reactive Protein (CRP)-based), and Visual Analogue Scale (VAS) measures, were evaluated at baseline and at 6, 12, and 24 months. Adjusted hazard ratios (aHRs) for discontinuing SECU were determined using multivariate Cox regression models. Results: SECU survival at 24 months was 63.24%, significantly higher in mixed PsA compared to perPsA ( p = 0.036). In the overall PsA population, DAPSA scores decreased significantly at 6 months, and further at 24 months (all p < 0.0001). In mixed PsA, ASDAS-CRP scores were significantly reduced at 6 months and remained stable through 24 months (all p < 0.0001). VAS pain scores also improved already at 6 months and continued to improve at 24 months (all p < 0.0001). Higher age (aHR = 0.98, 95% confidence interval (CI): 0.96–0.99, p = 0.007) and lower baseline DAPSA scores (aHR = 1.02, 95% CI: 1.01–1.03, p = 0.014) were associated with greater persistence of SECU treatment. SECU was well tolerated, with no serious adverse events. Conclusion: SECU showed sustained clinical improvements in both peripheral and axial involvement of PsA patients over 24 months, with higher persistence observed in mixed PsA patients. Our findings highlight the favorable clinical and safety profile of SECU in real world.https://doi.org/10.1177/1759720X251315138 |
| spellingShingle | Giuseppe Lopalco Maria Morrone Fabiola Atzeni Chiara Bazzani Francesco Paolo Bianchi Francesco Paolo Cantatore Roberto Caporali Antonio Carletto Alberto Cauli Maria Sole Chimenti Sergio Colella Fabrizio Conti Addolorata Corrado Ennio Giulio Favalli Alberto Floris Marco Fornaro Rosario Foti Roberta Foti Elena Fracassi Bruno Frediani Stefano Gentileschi Roberto Gorla Elisa Gremese Emanuela Praino Roberta Ramonda Cinzia Rotondo Marco Sebastiani Angelo Semeraro Gianfranco Ferraccioli Giovanni Lapadula Florenzo Iannone Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry Therapeutic Advances in Musculoskeletal Disease |
| title | Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry |
| title_full | Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry |
| title_fullStr | Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry |
| title_full_unstemmed | Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry |
| title_short | Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry |
| title_sort | efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes insights from the italian gisea registry |
| url | https://doi.org/10.1177/1759720X251315138 |
| work_keys_str_mv | AT giuseppelopalco efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT mariamorrone efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT fabiolaatzeni efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT chiarabazzani efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT francescopaolobianchi efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT francescopaolocantatore efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT robertocaporali efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT antoniocarletto efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT albertocauli efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT mariasolechimenti efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT sergiocolella efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT fabrizioconti efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT addoloratacorrado efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT enniogiuliofavalli efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT albertofloris efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT marcofornaro efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT rosariofoti efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT robertafoti efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT elenafracassi efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT brunofrediani efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT stefanogentileschi efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT robertogorla efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT elisagremese efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT emanuelapraino efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT robertaramonda efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT cinziarotondo efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT marcosebastiani efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT angelosemeraro efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT gianfrancoferraccioli efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT giovannilapadula efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry AT florenzoiannone efficacyandretentionrateofsecukinumabinpsoriaticarthritisacrossdifferentclinicalphenotypesinsightsfromtheitaliangisearegistry |